Novavax: EMA gives green light for approval

20.12.2021

After a thorough evaluation, the responsible committee concluded that ‘the EU criteria on efficacy, safety and quality are met’, the EMA announced. The Novavax vaccine, trade name Nuvaxovid, is injected in two doses about three weeks apart. According to the studies, it is highly effective with an infection protection of around 90 percent. However, it is unclear how strong its effect against the Omicron variant is. The Novavax compound is neither an mRNA vaccine, like those from BioNTech and Moderna, nor a vector vaccine, like those from AstraZeneca and Johnson & Johnson. It contains tiny particles composed of a laboratory-produced version of the Sars-CoV-2 spike protein. They are supposed to ensure that the body produces antibodies and T cells against the virus.